relyvrio
Relyvrio is a combination medicine containing Sodium Phenylbutyrate and Taurursodiol.
Sodium Phenylbutyrate and Taurursodiol · by Amylyx
Key facts
- Active ingredient
- Sodium Phenylbutyrate and Taurursodiol
- Strength
- Sodium Phenylbutyrate 3GM/PACKET; Taurursodiol 1GM/PACKET
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Amylyx
- FDA application
- NDA216660
- Availability
- Discontinued (per FDA)
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- Is there a coupon or discount for Relyvrio?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Relyvrio. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Relyvrio?
- Relyvrio is marketed by Amylyx. You can see Amylyx's full profile, rating, and other products on pharmaranks.
- Is Relyvrio a brand-name or generic drug?
- Relyvrio is a brand-name product with the active ingredient Sodium Phenylbutyrate and Taurursodiol.
- Is Relyvrio available over the counter?
- No. Relyvrio is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- Is Relyvrio FDA-registered?
- Relyvrio is on record with the U.S. FDA under application number NDA216660. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about SODIUM PHENYLBUTYRATE AND TAURURSODIOL
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1 reports naming SODIUM PHENYLBUTYRATE AND TAURURSODIOL — the active ingredient in Relyvrio, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- ankle fracture1 reports
- arthralgia1 reports
- covid-191 reports
- depressed mood1 reports
- dyspnoea1 reports
- emotional distress1 reports
- fall1 reports
- micturition urgency1 reports
Read these as a signal, not a rate. A report does not mean SODIUM PHENYLBUTYRATE AND TAURURSODIOL caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
benzamycin
Benzoyl Peroxide and Erythromycin
colazal
Balsalazide Disodium
cuprimine
Penicillamine
mysoline
Primidone
retin-a
Tretinoin
tolak
Fluorouracil
Compare Relyvrio head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
relyvrio
New